Casdin Capital, LLC
Annual return
—
SPY
—
Alpha
—
Invested
$2.6B
Holdings
40
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsIn development
Quarterly performance not yet computed for this fund.
The metrics pipeline computes return / SPY benchmark / alpha per quarter from this fund's 13F holdings and the SPY adj-close. It hasn't produced enough quarters here yet — the chart fills in automatically once at least two are on record.
Top holdings · current snapshot
Source: 13F-HR01
$RVMD
REVOLUTION MEDICINES INC
Q3 2025: Sold 8.3% (2.89M → 2.65M shares)
19.1%
02
$WGS
GENEDX HOLDINGS CORP
Q3 2025: Sold 14.3% (3.51M → 3.01M shares)
14.7%
03
$RLAY
RELAY THERAPEUTICS INC
Q3 2025: Sold 0.5% (11.40M → 11.34M shares)
10.9%
04
$BLFS
BIOLIFE SOLUTIONS INC
Q3 2025: Sold 13.0% (7.71M → 6.71M shares)
8.7%
05
$LAB
STANDARD BIOTOOLS INC
Q3 2025: Increased +1.9% (76.08M → 77.56M shares)
6.2%
06
$ILMN
ILLUMINA INC
Q3 2025: Sold 18.6% (645.0k → 525.0k shares)
5.0%
07
$GPCR
STRUCTURE THERAPEUTICS INC
Q3 2025: Increased +26.9% (1.23M → 1.56M shares)
4.3%
08
$TXG
10X GENOMICS INC
Held since at least Q1 2024
3.7%
09
$DNLI
DENALI THERAPEUTICS INC
Q2 2025: Sold 10.1% (990.0k → 890.0k shares)
2.7%
10
$BEAM
BEAM THERAPEUTICS INC
Q3 2025: Increased +10.3% (1.45M → 1.60M shares)
2.4%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Source data: SEC EDGAR · 13F-HR filings · Last refreshed 05:57 UTC.